Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Lung Neoplasms 2Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Lymphoma 1Leukemia, Myeloid, Acute 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

Carboplatin 46Paclitaxel 31pembrolizumab 25Cyclophosphamide 24Nivolumab 14Bevacizumab 14Topotecan 12Gemcitabine 12liposomal doxorubicin 11Filgrastim 11Cisplatin 11fludarabine 10Peripheral Blood Stem Cell Transplantation 10olaparib 8aldesleukin 7durvalumab 6Oxaliplatin 6Ipilimumab 6Interleukin-2 6Docetaxel 6niraparib 5epacadostat 5cemiplimab 5Ifosfamide 5Fulvestrant 5rucaparib 4poly ICLC 4pazopanib 4avelumab 4atezolizumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Ovarian Neoplasms × belinostat × Clear all
NCT00421889 2015-07-28

A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse Treatment

Valerio Therapeutics

Phase 1/2 Completed
80 enrolled 19 charts
GenitourinaryGynecologic

Carcinoma, Ovarian Epithelial, Urinary Bladder Neoplasms, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡